Dr. Sam chopra FRACS(Urol)

Urologist with specialist interest in Robotic and minimally invasive surgery for all urological cancers

[World Bladder Cancer Patient Coalition @WorldBladderCan]

If you or someone you love has faced #bladdercancer we would love to hear your story.

Sharing your journey brings hope, raises awareness & helps others feel less alone. 👉 https://t.co/USyoPVJznZ

#BladderCancerStories

[World Bladder Cancer Patient Coalition @WorldBladderCan]

Prof Bente Thoft Jensen, Prof Shingai Mutambirwa & Alessandro Boni wrote this piece together to call for three things:
✅ Continence on the agenda at every #bladdercancer appointment.
✅ Continence preparation built into care before major surgery.
✅ Honest information given early enough to shape patients' choices.

Surviving bladder cancer is the beginning. Living well afterwards is what we should all be working towards. 💪 👉 https://t.co/DGq1mGGD9l

[World Bladder Cancer Patient Coalition @WorldBladderCan]

#Bladdercancer is more common in men & incontinence after treatment is something many face in silence. It doesn't have to be that way. Seeking support is the right move. Let's break the stigma. #WCW2026 #continencematters

[Dr. Sam chopra FRACS(Urol) @DoctorChopra]

#Bladder cancer

[Dr. Sam chopra FRACS(Urol) @DoctorChopra]

Rare but aggressive bladder cancers ! #BCAN , #USANZ

[Dr. Sam chopra FRACS(Urol) @DoctorChopra]

Rare but aggressive bladder cancers ! #BCAN , #USANZ

[Dr. Sam chopra FRACS(Urol) @DoctorChopra]

https://t.co/PlvBtOVUkz

[Dr. Sam chopra FRACS(Urol) @DoctorChopra]

#usanz #PCFA

[Dr. Sam chopra FRACS(Urol) @DoctorChopra]

https://t.co/NmHteB1ZSF

[Dr. Sam chopra FRACS(Urol) @DoctorChopra]

https://t.co/NmHteB1ZSF

[Dr. Sam chopra FRACS(Urol) @DoctorChopra]

https://t.co/NmHteB1ZSF

[Fernando GomezSancha @fgomsan]

Transurethral resection of bladder tumours has a 200-year history. This review covers the arc: from Desormeaux's 1853 Lichtleiter to modern en bloc TURBT and laser techniques. Historical perspective.
https://t.co/1h8uYy1l6h

[UroToday.com @urotoday]

Retrospective cohort analysis of Blue-Light cystoscopy using a claims database. @MarkTysonMD @MayoClinic joins @UroDocAsh @UTMDAnderson reviewing a real-world cost analysis of blue-light versus white-light cystoscopy, drawing on a matched Optum database cohort. Dr. Tyson notes the PHOTO trial found similar recurrence-free survival with higher costs in predominantly intermediate-risk patients. #WatchNow on UroToday > https://t.co/qNIPAEUUQx

[Fernando GomezSancha @fgomsan]

These videos from the AUA are amazing https://t.co/OgZ2T27eGO

[Afshine Emrani MD FACC @afshineemrani]

1/5
I'm a cardiologist. I'm 58 years old. I was born in Iran, exiled as a child, and rebuilt my life from nothing in a country that owed me nothing.
It took me decades to understand what I'm about to tell you.
I learned some of these lessons in medical school. Some in the cath lab at 3 AM. Some from Rumi and Rabbi Nachman. Some from patients who taught me more about living in their final hours than I learned in four years of residency.
I wish someone had given me these words at twenty. No one did. So I'm giving them to you now.

[Dr. Sam chopra FRACS(Urol) @DoctorChopra]

A new initiative to centralise patient care

[Matt Cooperberg @dr_coops]

And just like that, an era ended. Neoadj chemo before cystectomy is now a historical footnote #ev304 #keynoteb15 #ASCO26

[Tyler Seibert MD PhD @TylerSbrt]

Control arm not SoC is my biggest concern.

Patient wants surgery. But will he benefit from neoadjuvant approach vs. SoC evaluation of RP pathology + PSA (+/- biomarkers) and RT+/- ADT x6 months if needed? How to decide?

#ASCO26 @declangmurphy @dr_coops @wandering_gu @Prof_IanD

[Yüksel Ürün @DrYukselUrun]

Excellent discussion by @declangmurphy on a post-PROTEUS algorithm for high-risk prostate cancer.
Selection is becoming the new treatment frontier.

#ASCO26 @gu_onc
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

[MJosé Juan @mjuanfi81]

PROTEUS trial: perioperative ADT+apalutamide improved pCR (8.9 vs 1%,p<0.001) and MFS vs ADT+placebo (78.2 vs 73.5%, HR 0.80, p=0.02) in high-risk localized/locally advanced PC undergoing RP. Benefit is consistent, but patient selection matters.@OncoAlert
https://t.co/HL9aVS8nOg